Head of Hemoglobinopathies Commercialization

About the Department

The Strategy & Rare Disease (STARS) organization drives the long-term strategic direction of Novo Nordisk Inc. (NNI)/North America Operations (NAO) and leads all US commercial efforts for Novo Nordisk’s Rare Disease portfolio. The mandate of STARS is to facilitate the development and to coordinate the execution of the long-term strategy, defining a sustainable business model in US beyond a 5-year time horizon. This department serves as the insiders of the US market when informing and help shaping upstream decisions around future investments and assets. The Rare Disease portfolio includes products in the hemophilia and growth disorders therapeutic areas, new products in the pipeline, and products acquired through business development efforts in existing and new areas. The STARS team collaborates and partners with groups across NAO, Research & Early Development, Development, innovation hubs across NN, other affiliates, and global. We’re looking for individuals who are enterprise thinkers, inclusive leaders, and strong collaborators, as we embark on shaping our future.

 

The Position

The Hemoglobinopathies Commercialization Head is accountable to formulate, lead, align and champion the US Hemoglobinopathies commercialization approach overseeing assets for Sickle Cell and Beta Thalassemia leading the strategy for each asset as well as the portfolio to ensure success, while maintaining a deep focus on patients and stellar standards of care.

 

Leads and sets US strategic direction and business plans for the designated therapy area aligned to NN strategies. Informs portfolio strategy with TA-level priorities and implications. Role models an enterprise mindset while influencing functional leaders to align to the enterprise vision.

 

In coordination with headquarters, will develop and implement effective pre-launch plans to maximize revenue, market share and profitability goals. Has significant decision-making authority and influence on impacting revenue and profitability. Leads the assets and portfolio strategy planning processes to drive integrated customer centric strategies and programming.  Significant contributor to the global strategy for the TA by working closely with global marketing and medical leaders by participating in cross-functional and global Core Commercialization Teams.

 

Oversight of the Hemoglobinopathies TA influencing cross-functional members including Market Access, Medical Affairs, Commercial Operations, Finance, etc. Owns the Therapeutic Area Brand Plans and drives cross-functional alignment and execution on key brand decisions, takes informed chances and full ownership/responsibility of TA decisions.

 

Embody NN leadership behaviors, embracing innovation, leadership over process, empowerment and the value of time.

 

Relationships

Reports to the Head of the Rare Disease Business Unit and is a key contributor to the Rare Disease Leadership team. The Head of Hemoglobinopathies Commercialization is the primary interface with the heads of both commercial and non-commercial functions within NNI relative to the designated Therapeutic Area, their performance and business impact.

 

This role will oversee the Hemoglobinopathies marketing organization and will work closely with Global Marketing, Medical Affairs, Market Access, Commercial Excellence and Strategic Partnerships and Engagement to deliver on the Hemoglobinopathies ambition.

 

Essential Functions

• Strategic Planning and Performance:
  • Develop and execute the Hemoglobinopathies assets and portfolio strategies, aligning with overall company objectives
  • Responsible for the Profit & Loss (P&L) statement for the assigned therapeutic areas
  • Responsible for establishing financial performance metrics while ensuring revenue targets and profitability goals are met or exceeded post-launch
  • Define key performance metrics and establish mechanisms for tracking and reporting on the effectiveness of commercial marketing strategies and initiatives
• Integrated Strategy
  • Accountable fo